医疗器械 渠道积淀筑底，自研驱动与战略拓展打开成长空间 可孚医疗（301087.SZ） 证券研究报告/公司深度报告 2026 年 02 月 11 日 | 评级： | 买入（首次） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | | | 营业收入（百万元） | 2,854 | 2,983 | 3,384 | 4,098 | 5,100 | | 分析师：祝嘉琦 | | 增长率 yoy% | -4% | 5% | 13% | 21% | 24% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | 254 | 312 | 359 | 436 | 551 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | -16% | 23% | 15% | 22% | 26% | | | | 每股收益（元） | 1.22 | 1.49 | 1.72 | 2.09 | ...

医疗器械 渠道积淀筑底，自研驱动与战略拓展打开成长空间 可孚医疗（301087.SZ） 证券研究报告/公司深度报告 2026 年 02 月 11 日 | 评级： | 买入（首次） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | | | 营业收入（百万元） | 2,854 | 2,983 | 3,384 | 4,098 | 5,100 | | 分析师：祝嘉琦 | | 增长率 yoy% | -4% | 5% | 13% | 21% | 24% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | 254 | 312 | 359 | 436 | 551 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | -16% | 23% | 15% | 22% | 26% | | | | 每股收益（元） | 1.22 | 1.49 | 1.72 | 2.09 | ...

Group 1: Business Performance and Strategy - The company aims to enhance the operational quality of existing stores, with a reported revenue growth of over 20% year-on-year in the first half of 2025 [2] - The company plans to launch new products and strengthen online and offline channel collaboration to expand its hearing business [2] - The overseas business achieved nearly 100 million in revenue, with a year-on-year growth exceeding 200% [4] Group 2: Investments and Acquisitions - The company invested in NeuLink Medical in May 2024 to explore advanced hearing rehabilitation solutions through brain-machine interface technology [3] - In January 2025, the company completed a controlling acquisition of Shanghai Huazhou, enhancing its product line and overseas market channels [4] - The company also acquired a controlling stake in Ximan Na in June 2025, facilitating entry into the Hong Kong market [4] Group 3: Online Sales and Market Trends - The company has developed a comprehensive product matrix covering five major areas, maintaining strong sales performance on mainstream e-commerce platforms [6] - Interest e-commerce platforms have gained popularity, prompting the company to invest in innovative content to enhance brand visibility and product sales [6] Group 4: AI and Technology Development - The company is advancing AI applications across various medical devices, focusing on interconnectivity and data exchange [7] - The upcoming Kefu Health APP will integrate data from multiple devices to provide personalized health management solutions [7] Group 5: Core Product Strategy - The company focuses on core product categories that contribute significantly to revenue and have growth potential, including respiratory machines and hearing aids [8] - Continuous improvement in product quality and market share is a priority, with plans for iterative upgrades and cost reductions [8] Group 6: Respiratory Device Performance - The company's self-developed respiratory machines have received high consumer recognition, with sales rapidly increasing since late June 2025 [9]

Group 1: Company Performance - The company achieved a revenue of 2.983 billion CNY in 2024, representing a year-on-year growth of 4.53% [7] - The net profit attributable to shareholders was 312 million CNY, with a year-on-year increase of 22.60% [7] - The net profit excluding non-recurring gains and losses was 275 million CNY, showing a growth of 36.74% [7] - The net cash flow from operating activities reached 663 million CNY, up by 68.45% [7] Group 2: Market and Product Development - The company has established three research institutes focusing on medical electronics, biomedicine, and respiratory support, enhancing its R&D capabilities [2] - The self-developed ventilator has received high consumer recognition, with plans to launch a new generation of products [3] - The hearing aid segment reported a revenue of 273 million CNY in 2024, a growth of 37.86%, despite a loss of 43.25 million CNY due to new store performance [4] Group 3: Strategic Initiatives - The company aims for high-quality, sustainable development through diversified marketing strategies during promotional events [5] - Future dividend policies will focus on stable returns to shareholders while ensuring sustainable company growth [6] - The company is leveraging the "Healthy China" strategy and the aging population trend to drive demand for home medical devices [8] Group 4: Industry Outlook - The medical device industry is expected to grow due to increased health awareness and technological advancements [9] - Companies with strong R&D and operational capabilities are likely to maintain competitiveness, while those with product homogeneity face challenges [9] - The company plans to enhance its core product innovation and expand its international market presence [9]